MS&L wins Glaxo diabetes work

Glaxo Wellcome has handed PR for the UK launch of a new diabetes product Romozin (troglitazone) to Manning Selvage and Lee, following a five-way pitch.

Glaxo Wellcome has handed PR for the UK launch of a new diabetes

product Romozin (troglitazone) to Manning Selvage and Lee, following a

five-way pitch.



The campaign,which is believed to carry a six-figure fee, will target

general practitioners and healthcare professionals through the medical

press and the medical and science pages of the national press.



MS&L will be responsible for launching the product and helping to

re-establish Glaxo Wellcome in the diabetes field.



’Glaxo were involved in the diabetes field in the 1970s as an insulin

supplier, but it has little presence at the moment,’ said a Glaxo

spokesman.



Romozin, the first of a new class of drugs, treats non-insulin dependent

diabetes mellitus. ’If you don’t treat non-insulin dependent diabetes

properly there are a lot of related problems, like heart disease,

amputations and obesity,’ said Henrietta Noyes, director of healthcare

at MS&L.



’The main message stems from Glaxo Wellcome’s belief that diabetes is an

under-estimated illness,’ said the Glaxo spokesman.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.